Published in Nat Genet on July 30, 2006
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
miRiad roles for the miR-17-92 cluster in development and disease. Cell (2008) 8.02
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer (2009) 5.47
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
The microcosmos of cancer. Nature (2012) 4.50
MicroRNAs in cancer. Annu Rev Pathol (2009) 4.47
Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol (2007) 4.16
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3.68
MicroRNAs add a new dimension to cardiovascular disease. Circulation (2010) 3.64
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol (2010) 3.15
MicroRNA regulatory networks in cardiovascular development. Dev Cell (2010) 3.09
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A (2008) 3.03
microRNA involvement in human cancer. Carcinogenesis (2012) 2.98
MicroRNA biogenesis pathways in cancer. Nat Rev Cancer (2015) 2.67
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57
MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol (2009) 2.49
Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med (2014) 2.47
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
MicroRNA and cancer--focus on apoptosis. J Cell Mol Med (2009) 2.44
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ (2013) 2.41
AngiomiRs--key regulators of angiogenesis. Curr Opin Genet Dev (2009) 2.40
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
MicroRNAs as novel regulators of angiogenesis. Circ Res (2009) 2.33
Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest (2010) 2.32
The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol (2008) 2.29
Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J (2009) 2.21
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest (2008) 2.15
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res (2011) 2.06
Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans. Nat Genet (2011) 2.04
MicroRNA in lung cancer. Br J Cancer (2010) 1.97
Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol (2009) 1.93
MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One (2011) 1.90
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
MicroRNAs regulate ocular neovascularization. Mol Ther (2008) 1.89
MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer (2009) 1.87
MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell (2011) 1.84
MicroRNAs in tumorigenesis: a primer. Am J Pathol (2007) 1.83
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology (2009) 1.76
Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J Physiol (2011) 1.71
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther (2009) 1.61
The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res (2010) 1.60
Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene (2011) 1.60
MicroRNAs: opening a new vein in angiogenesis research. Sci Signal (2009) 1.58
Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol (2010) 1.58
Myc: Maestro of MicroRNAs. Genes Cancer (2010) 1.58
MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling. Circ Res (2012) 1.56
microRNA and stem cell function. Cell Tissue Res (2007) 1.54
VEGF-Induced Expression of miR-17-92 Cluster in Endothelial Cells Is Mediated by ERK/ELK1 Activation and Regulates Angiogenesis. Circ Res (2015) 1.52
Causes and consequences of microRNA dysregulation. Cancer J (2012) 1.51
Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res (2012) 1.50
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA (2009) 1.48
An overview of microRNAs. Adv Drug Deliv Rev (2015) 1.48
The VHL-dependent regulation of microRNAs in renal cancer. BMC Med (2010) 1.46
"Myc'ed messages": myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet (2007) 1.45
MicroRNA expression profiling in mild asthmatic human airways and effect of corticosteroid therapy. PLoS One (2009) 1.44
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A (2010) 1.43
Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest (2011) 1.42
The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J (2012) 1.42
A computational screen for mouse signaling pathways targeted by microRNA clusters. RNA (2008) 1.41
MicroRNAs and cardiovascular diseases. FEBS J (2011) 1.41
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal (2009) 1.40
Computational approaches for microRNA studies: a review. Mamm Genome (2009) 1.39
STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev (2012) 1.38
c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem (2013) 1.37
The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence. PLoS One (2008) 1.37
MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev (2012) 1.34
N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene (2008) 1.34
Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle (2008) 1.33
Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol (2007) 1.32
MicroRNAs: molecular features and role in cancer. Front Biosci (Landmark Ed) (2012) 1.32
mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev (2013) 1.32
Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet (2012) 1.31
Micromanaging vascular biology: tiny microRNAs play big band. J Vasc Res (2009) 1.31
Differential expression of microRNAs in different disease states. Circ Res (2012) 1.30
MYC regulates the non-coding transcriptome. Oncotarget (2014) 1.29
MicroRNA networks in mouse lung organogenesis. PLoS One (2010) 1.28
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol (2008) 1.25
MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis (2014) 1.24
MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem (2010) 1.23
miRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med (2013) 1.21
The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron (2010) 1.21
Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun (2009) 1.21
MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle (2012) 1.20
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Human MicroRNA targets. PLoS Biol (2004) 34.51
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA (2004) 7.71
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer (2006) 5.37
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev (2000) 5.16
CCN proteins: multifunctional signalling regulators. Lancet (2004) 4.88
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell (1999) 4.38
Retracted Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell (2003) 3.56
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev (2002) 3.16
Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J (2001) 2.79
B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol (2003) 1.68
Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res (2004) 1.65
The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol (2004) 1.61
Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene (2000) 1.61
An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ (2000) 1.54
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res (2004) 1.48
Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem (1996) 1.46
Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene (1997) 1.42
Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res (2000) 1.28
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res (2002) 1.27
Tumorigenic conversion of p53-deficient colon epithelial cells by an activated Ki-ras gene. J Clin Invest (1998) 1.05
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
A hexanucleotide element directs microRNA nuclear import. Science (2007) 5.71
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A (2008) 5.15
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol (2007) 3.68
microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet (2007) 3.63
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A (2008) 3.10
Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell (2009) 3.05
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics (2006) 2.96
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Erythroid GATA1 function revealed by genome-wide analysis of transcription factor occupancy, histone modifications, and mRNA expression. Genome Res (2009) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology (2011) 2.61
Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach. Gastroenterology (2005) 2.53
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Therapeutic hypothermia in acute liver failure: a multicenter retrospective cohort analysis. Liver Transpl (2015) 2.44
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 2.44
Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell (2011) 2.40
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. Gastrointest Endosc (2002) 2.30
Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology (2012) 2.26
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Steroid use in acute liver failure. Hepatology (2013) 2.23
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther (2006) 2.15
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol (2006) 2.01
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther (2009) 2.01
Telomere shortening exposes functions for the mouse Werner and Bloom syndrome genes. Mol Cell Biol (2004) 1.99
A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther (2002) 1.96
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol (2013) 1.95
Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos (2009) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A (2005) 1.91
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Cell-cell contact globally activates microRNA biogenesis. Proc Natl Acad Sci U S A (2009) 1.89
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol (2011) 1.85
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest (2012) 1.85
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther (2011) 1.76
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology (2009) 1.76
Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol (2006) 1.74
Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther (2009) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene (2002) 1.70
Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res (2004) 1.65
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther (2009) 1.61
Gc-globulin and prognosis in acute liver failure. Liver Transpl (2005) 1.59
Myc: Maestro of MicroRNAs. Genes Cancer (2010) 1.58